Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy: Results of the CAMI-GUIDE study

European Heart Journal

Volumn 33, Issue 11, 2012, Pages 1344-1350

  Biasucci, Luigi M ^a   Bellocci, Fulvio ^a   Landolina, Maurizio ^b   Rordorf, Roberto ^b   Vado, Antonello ^c   Menardi, Endrj ^c   Giubilato, Giovanna ^a   Orazi, Serafino ^d   Sassara, Massimo ^e   Castro, Antonello ^f   Massa, Riccardo ^g   Kheir, Antoine ^h   Zaccone, Gabriele ⁱ   Klersy, Catherine ^b   Accardi, Francesco ^j   Crea, Filippo ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c S CROCE E CARLE HOSPITAL   (Italy)

^d SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^e BELCOLLE HOSPITAL   (Italy)

^f SANDRO PERTINI HOSPITAL   (Italy)

^g SS Antonio e Biagio e Cesare Arrigo Hospital   (Italy)

^h Policlinico S Pietro   (Italy)

ⁱ S Giacomo Hospital   (Italy)

^j Boston Scientific   (Italy)

more..

Author keywords

Brain natriuretic peptide; C reactive protein; Implantable cardioverter defibrillator; Myocardial infarction; Sudden cardiac death

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYSTATIN C;

ADULT; AGED; ARTICLE; CARDIOVERSION; DEATH; DEFIBRILLATION; DEFIBRILLATOR; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMPLANTATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SUDDEN DEATH; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TACHYCARDIA, VENTRICULAR;

EID: 84861830092     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr487     Document Type: Article

References (50)

1. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-1940. (Pubitemid 26428217)
2. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-1890.
3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-883. (Pubitemid 34984635)
4. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151-2158. (Pubitemid 38637995)
5. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, Mc Nulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237. (Pubitemid 40110811)
6. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac- resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-2150.
7. Greenberg SM, Epstein AE, Deering T, Goldman DS, Ghidina M, Neason C, Proclemer A. A Comparison of ICD implantations in the United States vs. Italy. Pacing Clin Electrophysiol 2007;30:S143-S146. (Pubitemid 46121829)
8. Proclemer A, Ghidina M, Cicuttini G, Gregori D, Fioretti PM. Impact of the main implantable cardioverter-defibrillator trials for primary and secondary prevention in Italy: a survey of the national activity during the years 2001-2004. Pacing Clin Electrophysiol 2006;29:S20-S28. (Pubitemid 44813756)
9. Pedretti RF, Curnis A, Massa R, Morandi F, Tritto M, Manca L, Occhetta E, Molon G, De Ferrari GM, Sarzi Braga S, Raciti G, Klersy C, Salerno-Uriarte JA. Proportion of patients needing an implantable cardioverter defibrillator on the basis of current guidelines: impact on healthcare resources in Italy and the United States. Data from the ALPHA study registry. Europace 2010;12: 1105-1111.
10. Every N, Hallstrom A, McDonald KM, Parsons L, Thom D,Weaver D, Hlatky MA. Risk of sudden vs. nonsudden cardiac death in patients with coronary artery disease. Am Heart J 2002;144:390-396.
11. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith SC Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano J. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the ACC/AHA Task Force and the ESC Committee for Practice Guidelines. Circulation 2006;114:e385-e484.
12. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J 2002;144:440-448.
13. Buxton AE, Moss AJ. Should everyone with an ejection fraction less than or equal to 30 receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction, or 30 should receive an implantable cardioverterdefibrillator. Circulation 2005;111:2537-2549. (Pubitemid 40696144)
14. Bigger JT Jr. Relationship between left ventricular dysfunction and ventricular arrhythmias after myocardial infarction. Am J Cardiol 1985;57:8B-14B.
15. Bailey JJ, Berson AS, Handelsman H, Hodges M. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. J Am Coll Cardiol 2001;38:1902-1911. (Pubitemid 33116562)
16. Schwartz RS, Burke A, Farb A, Kaye D, Lesser JR, Henry TD, Virmani R. Microemboli and microvascular obstruction in acute coronary thrombosis and sudden coronary death: relation to epicardial plaque histopathology. J Am Coll Cardiol 2009;54:2167-2173.
17. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004; 95:754-763. (Pubitemid 39390577)
18. Pogwizd SM, Hoyt RH, Saffitz JE, Corr PB, Cox JL, Cain ME et al. Reentrant and focal mechanisms underlying ventricular tachycardia in the human heart. Circulation 1992;86:1872-1887.
19. Mehta D, Curwin J, Gomes JA, Fuster V. Sudden death in coronary artery disease. Acute ischemia vs. myocardial substrate. Circulation 1997;96:3215-3223. (Pubitemid 27500128)
20. Panteghini M, Apple FS, Christenson RH, Dati F, Mair J, Wu AH. Proposals from IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD): recommendations on use of biochemical markers of cardiac damage in acute coronary syndromes. Scand J Clin Lab Invest 1999;230:103-112. (Pubitemid 29279362)
21. Bellocci F, Biasucci LM, Gensini GF, Padeletti L, Raviele A, Santini M, Giubilato G, Landolina M, Biondi-Zoccai G, Raciti G, Sassara M, Castro A, Kheir A, Crea F. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter defibrillators: design of the C-reactive protein assessment after Myocardial Infarction to Guide Implantation of Defibrillator (CAMI GUIDE) study. J Cardiovasc Med 2007;8:293-299. (Pubitemid 46586670)
22. Biasucci LM. CDC/AHA workshop on markers of inflammation and cardiovascular disease application to clinical and public health practice clinical use of inflammatory markers in patients with cardiovascular diseases. A background paper. Circulation 2004;110:e560-e567.
23. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003;108:2993-2999. (Pubitemid 37553568)
24. Currie CJ, Poole CD, Conway P. Evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality. Heart 2008;94:457-462. (Pubitemid 351441401)
25. Filion KB, Xie X, van der Avoort CJ, Dendukuri N, Brophy JM. Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study. Int J Technol Assess Health Care 2009;25:151-160.
26. Goldberger JJ. Evidence-based analysis of risk factors for sudden cardiac death. Heart Rhythm 2009;6:S2-S7.
27. de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischemia and infarction. Br Heart J 1982;47:239-243. (Pubitemid 12179920)
28. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-442.
29. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, Pestaner J, Smialek J, Virmani R. Elevated C-reactive protein values and atherosclerosis in sudden coronary death-association with different pathologies. Circulation 2002; 105:2019-2023. (Pubitemid 34465262)
30. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002;105:2592-2599.
31. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, Hafner G, Treude R, Othman H, Hofmann KP, Meyer J. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:901-908. (Pubitemid 34310284)
32. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Imflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-978.
33. Biasucci LM, Giubilato G, Biondi-Zoccai G, Sanna T, Liuzzo G, Piro M. C reactive protein is associated with malignant ventricular arrhythmias in patients with ischaemia with implantable cardioverter-defibrillator. Heart 2006;92:1147-1148. (Pubitemid 44125242)
34. Streitner F, Kuschyk J, Veltmann C, Ratay D, Schoene N, Streitner I, Brueckmann M, Schumacher B, Borggrefe M, Wolpert C. Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverterdefibrillator and an electrical storm. Cytokine 2009;47:166-167.
35. Konstantino Y, Kusniec J, Reshef T, David-Zadeh O, Mazur A, Strasberg B, Battler A, Haim M. Inflammatory biomarkers are not predictive of intermediateterm risk of ventricular tachyarrhythmias in stable CHF patients. Clin Cardiol 2007; 30:408-413. (Pubitemid 47312892)
36. Blangy H, Sadoul N, Dousset B, Radauceanu A, Fay R, Aliot E, Zannad F. Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace 2007;9:724-729. (Pubitemid 47371644)
37. Goldenberg I, Gillespie J, Moss AJ, Hall WJ, Klein H, McNitt S, Brown MW, Cygankiewicz I, Zareba W. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 2010; 122:1265-1271.
38. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005;112:1428-1434. (Pubitemid 41291768)
39. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009;120:2188-2196.
40. Kozdaǧ G, Ertaş G, Kiliç T, Acar E, Agir A, Sahin T, Cetin M, Bildirici U, Ural D. Elevated level of high-sensitivity C-reactive protein is important in determining prognosis in chronic heart failure. Med Sci Monit 2010;16:CR156-CR161.
41. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA III, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-1338.
42. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834-1843.
43. Deo R, Shlipak MG, Ix JH, Ali S, Schiller NB, Whooley MA. Association of cystatin C with ischemia in patients with coronary heart disease. Clin Cardiol 2009;32: E18-E22.
44. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115:173-179. (Pubitemid 46105715)
45. Verma A, Kilicaslan F, Martin DO, Minor S, Starling R, Marrouche NF, Almahammed S, Wazni OM, Duggal S, Zuzek R, Yamaji H, Cummings J, Chung MK, Tchou PJ, Natale A. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. Heart 2006;92:190-195. (Pubitemid 43131958)
46. Galante O, Amit G, Zahger D, Wagshal A, Ilia R, Katz A. B-type natruiretic peptide levels stratify the risk for arrhythmia among implantable cardioverter defibrillator patients. Clin Cardiol 2008;31:586-589.
47. Yu H, Oswald H, Gardiwal A, Lissel C, Klein G. Comparison of N-terminal probrain natriuretic peptide vs. electrophysiologic study for predicting future outcomes in patients with an implantable cardioverter defibrillator after myocardial infarction. Am J Cardiol 2007;100:635-639. (Pubitemid 47223138)
48. Scott PA, Barry J, Roberts PR, Morgan JM. Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis. Eur J Heart Fail 2009;11:958-966.
49. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003;108:250-252. (Pubitemid 36899010)
50. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148-2159.